Lexicon’s drug is an oral small molecule that blocks Acyl-CoA Synthetase 5, or ACSL5, a metabolic pathway that’s thought to be involved in energy expenditure and fat accumulation.

The small-molecule candidate, LX9851, is designed to increase the feeling of fullness by inhibiting ACSL5. Lexicon targeted the enzyme after finding that knocking out its gene resulted in mice ...

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, ...

LX9851, discovered and developed by Lexicon, is a potent and selective oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5) . ACSL5 plays a key role in the metabolic pathway which ...

LX9851, discovered and developed by Lexicon, is a potent and selective oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5). ACSL5 plays a key role in the metabolic pathway which ...